2 weeks Ago By Defense World Staff
Wells Fargo & Company MN lessened its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.
The firm owned 59,520 shares of the biopharmaceutical company’s stock after selling 936 shares during the quarter. Wells Fargo & Company MN owned approximately 0.08% of Xenon Pharmaceuticals worth $2,333,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its holdings in Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter.
Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 13,903 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Xenon Pharmaceuticals by 1,263.
2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after buying an additional 905,129 shares during the period.
Harbor Capital Advisors Inc. lifted its position in Xenon Pharmaceuticals by 3.7% during the 4th quarter.
Harbor Capital Advisors Inc. now owns 49,818 shares of the biopharmaceutical company’s stock valued at $1,953,000 after acquiring an additional 1,755 shares during the period. Elmwood Wealth Management Inc.
raised its stake in Xenon Pharmaceuticals by 44.7% during the fourth quarter. Elmwood Wealth Management Inc.
now owns 11,007 shares of the biopharmaceutical company’s stock valued at $431,000 after buying an additional 3,400 shares during the last quarter. Finally, Assenagon Asset Management S.A.
boosted its holdings in Xenon Pharmaceuticals by 12.4% in the fourth quarter. Assenagon Asset Management S.
A. now owns 238,522 shares of the biopharmaceutical company’s stock worth $9,350,000 after acquiring an additional 26,235 shares in the last quarter. Hedge funds and other institutional investors own 95.
45% of the company’s stock. Xenon Pharmaceuticals Stock PerformanceShares of Xenon Pharmaceuticals stock opened at $37.62 on Friday.
The stock has a 50 day moving average price of $34.80 and a 200-day moving average price of $38.68.
The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -13.34 and a beta of 1.
21. Xenon Pharmaceuticals Inc. has a one year low of $26.
74 and a one year high of $46.00. Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last issued its earnings results on Thursday, February 27th.
The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.
05. Sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -3.
1 earnings per share for the current fiscal year. Insider Buying and SellingIn other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $40.
50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares in the company, valued at $1,267,731.
This represents a 34.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
5.52% of the stock is owned by insiders. Analyst Upgrades and DowngradesSeveral brokerages recently commented on XENE.
William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th.
StockNews.com upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. The Goldman Sachs Group cut their price target on Xenon Pharmaceuticals from $60.
00 to $52.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Finally, Royal Bank of Canada restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th.
One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.
78.Check Out Our Latest Report on XENEXenon Pharmaceuticals Profile (Free Report)Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See AlsoFive stocks we like better than Xenon PharmaceuticalsWhat to Know About Investing in Penny StocksShort Sellers Gave Up on These 3 Names RecentlyWhat Investors Need to Know to Beat the Market3 Boring Stocks Outperforming the Market This YearWhat Are Treasury Bonds?If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy.
